March 18, 2024
Idorsia Ltd (SIX: IDIA) today announced that it has successfully closed the transaction with Viatris Inc. (NASDAQ: VTRS), a global healthcare company, for the global research and development collaboration, focused on the development and commercialization of two innovative compounds, selatogrel and cenerimod, discovered by Idorsia.
The upfront consideration of USD 350 million has now been fully paid by Viatris to Idorsia.
Further details will be provided with the combined Full Ye